Note: Ingredients listed on restricted chemical lists
EC/CAS
200-338-0/57-55-6
Name of the chemical
1,2-propanediol
Concentration
>=50-<70
General Information
Version
8.7
Revision date
2024-09-06
Product name
Protease from Bacillus sp
1.2.1 Relevant identified uses
Laboratory chemicals, Synthesis of substances
1.2.2. Uses advised against
The product is being supplied under the TSCA R&D Exemption
Emergency telephone
800-424-9300, +1-703- 527-3887
Icons in SDS
Company Information
company name
Sigma-Aldrich Inc
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H318, H334, H401, H412
Hazard statements
Code
Statements
H318
Causes serious eye damage
Section 2
SECTION 2: Hazards identification
Classification of the substance or mixture
Signal word
Danger
Hazard statements
H318 Causes serious eye damage. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H401 Toxic to aquatic life. H412 Harmful to aquatic life with long lasting effects.
Precautionary statements
P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P273 Avoid release to the environment. P280 Wear eye protection/ face protection. P285 In case of inadequate ventilation wear respiratory protection. P304 + P341 IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. P305 + P351 + P338 + IF IN EYES: Rinse cautiously with water for several minutes. P310 Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor. P501 Dispose of contents/ container to an approved waste disposal plant.
2.3 Other hazards
- none
2.1 Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) Serious eye damage (Category 1), H318 Respiratory sensitization (Category 1), H334 Short-term (acute) aquatic hazard (Category 2), H401 Long-term (chronic) aquatic hazard (Category 3), H412 For the full text of the H-Statements mentioned in this Section, see Section 16.
